Q-omics provides the consensus-scored UBL5 profile across patient tissues and cancer cell-line models. UBL5 expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, UBL5 is differentially expressed in 11, with the highest sampling consensus in LIHC. Additionally, UBL5 RNA expression shows 19,627 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KICH, LIHC, and THYM as cancer lineages where UBL5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for UBL5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes UBL5 survival associations across molecular data types. UBL5 RNA expression shows survival associations in the most cancer types (29), followed by mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible UBL5 RNA expression–survival associations across cancer types. High UBL5 expression shows unfavorable associations in KICH, UVM, ESCA, ACC, LGG and UCS. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KICH as the clearest survival context for UBL5 RNA expression.
This table summarizes UBL5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 4. The strongest signals are observed in LIHC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for UBL5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. UBL5 shows higher tumor expression in LIHC, HNSC, BRCA, BLCA, COAD and CHOL. The LIHC box plot shows higher UBL5 RNA expression in tumor versus normal tissue (log2 FC = +1.022, t-test p < 0.001).
This table shows molecular features associated with UBL5 in patient tissues and cancer cell lines. In patient samples, UBL5 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, UBL5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and SOFT_TISSUE.
